Background: Emphysematous pyelonephritis (EPN) is a necrotizing infection of the kidney and the surrounding tissues associated with considerable mortality. We aimed to formulate a score that classifies the risk of mortality in patients with EPN at hospital admission. Materials and methods: Patients diagnosed with EPN between 2013 and 2020 were retrospectively included. Data from 15 centers (70%) were used to develop the scoring system, and data from 7 centers (30%) were used to validate it. Univariable and multivariable logistic regression analyses were performed to identify independent factors related to mortality. Receiver operating characteristic curve analysis was performed to construct the scoring system and calculate the risk of mortality. A standardized regression coefficient was used to quantify the discriminating power of each factor to convert the individual coefficients into points. The area under the curve was used to quantify the scoring system performance. An 8-point scoring system for the mortality risk was created (range, 0–7). Results: In total, 570 patients were included (400 in the test group and 170 in the validation group). Independent predictors of mortality in the multivariable logistic regression were included in the scoring system: quick Sepsis-related Organ Failure Assessment score ≥2 (2 points), anemia, paranephric gas extension, leukocyte count >22,000/μL, thrombocytopenia, and hyperglycemia (1 point each). The mortality rate was <5% for scores ≤3, 83.3% for scores 6, and 100% for scores 7. The area under the curve was 0.90 (95% confidence interval, 0.84–0.95) for test and 0.91 (95% confidence interval, 0.84–0.97) for the validation group. Conclusions: Our score predicts the risk of mortality in patients with EPN at presentation and may help clinicians identify patients at a higher risk of death.
1 January 2023 in TURKISH JOURNAL OF MEDICAL SCIENCES
Background/aim: Sacral neuromodulation (SNM) is a minimally invasive treatment that modulates spinal reflexes to regulate bladder, urinary sphincter, and pelvic floor and has successfully been used in the treatment of refractory voiding dysfunctions. The aim of this study was to present our experience with SNM in a tertiary referral center with the largest number of patients and review the safety and efficacy of the procedure. Materials and methods: A total of 42 patients with refractory lower urinary tract symptoms were included into the study. After an initial test period, patients who showed more than 50% improvement in their symptoms underwent the second stage of SNM. Twelve patients had overactive bladder (OAB), bladder pain syndrome/interstitial cystitis (BPS/IC) and 17 had urinary retention. The clinical success was examined during follow-up by voiding diary, urodynamics, and global response assessment. Results: Between February 2015 and December 2020, a total of 29 patients underwent stages I&II SNM procedures. The mean ages of patients in OAB/BPS group and retention group were 40 (37-57 years) and 35 (27-44 years), respectively. Mean follow-up time was at least 1 year. Overall, 58.5% success rate was observed in OAB, BPS/IC, and urinary retention groups. Global response assessment score in both groups increased significantly (p = 0.001). No statistically significant difference was found between success or failure rates when sex and age were variable parameters (p > 0.05). Conclusion: SNM appears to be an effective and safe treatment option in restoring voiding dysfunctions in patients with refractory idiopathic and neurogenic voiding dysfunctions. Our initial series revealed favorable results; however, further studies with larger series and longer follow-up are needed.
2 July 2021 in International Urology and Nephrology
Background: To demonstrate that the CA19-9/creatinine level could be a potential biomarker in children with obstruction by including ureteropelvic junction obstruction (UPJO) patients and comparing them not only with healthy controls but also with children with non-obstructive hydronephrosis (HN). Materials and methods: Children with HN and healthy controls with no HN were prospectively enrolled into study from March 2021 to December 2022. The children with HN were divided into two separate groups. Group 1 consisted of children with UPJO, while Group 2 included children with lower urinary tract dysfunction (LUTD). Data collected from study and control groups included age, gender, spot urine CA 19 − 9/Cr ratio at the initial visit and at the 6-month follow-up, the Society of Fetal Urology (SFU) grade, antero-posterior (AP) diameter, renal function and diuretic response on mercaptoacetyltriglycine (MAG-3) dynamic renal scintigraphy and surgical or conservative management selection. Spot urine CA 19 − 9 levels were measured using the ELISA method. Results: Out of 283 children, Group 1 consisted of 40 children (11 girls, 29 boys; median age: 7 years), Group 2 comprised 18 children (10 girls, 8 boys; median age:8 years) and 225 healthy controls (83 girls, 142 boys; median age: 8 years). The spot urine CA 19 − 9/Cr ratio was significantly higher in the Group 1 and 2 compared to controls (respectively 86.7, 64.5, 47.1 U/mg Cr, p = 0.0001). When the two patient groups with HN were compared with each other, no statistically significant difference was observed in the urinary CA19-9/creatinine levels ( p = 0.358). No correlation was found between CA 19 − 9/Cr ratio and HN severity and/or dynamic renal scintigraphy findings. Surgical management of unilateral UPJO revealed a decrease in CA 19 − 9/Cr in the study group. Conclusion: This study suggests that the spot urine CA 19 − 9/creatinine ratio may serve as a promising, non-invasive biomarker for distinguishing children with unilateral UPJO and non-obstructive HN from healthy controls. Although elevated levels in patients and postoperative decline were observed, its inability to predict HN severity or the necessity for surgical intervention limits its clinical utility. Keywords: CA19-9, biomarker, ureteropelvic junction obstruction, hydronephrosis, lower urinary tract dysfunction